secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyell Immunopharma, Inc. (LYEL)
CIK:        0001806952
Form:       8-K
Filed at:   2025-06-09T23:59:59+00:00
Accession:  0001193125-25-137853
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Lyell Immunopharma appoints Mark Bachleda to Board, expanding size to 8
-----------------------------------------------------------------------

- Board increased from 7 to 8 directors; Mark Bachleda, Pharm.D., M.B.A., appointed as Class I director effective June 9, 2025.
- Term expires at 2028 annual meeting; compensation per non-employee director policy adjusted for 1-for-20 reverse stock split.
- Standard indemnification agreement entered with Dr. Bachleda.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806952/000119312525137853/0001193125-25-137853-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806952/000119312525137853/d940968d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-137853

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer